Trials / Terminated
TerminatedNCT06009237
A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of ABBV-903 or placebo in healthy adult Japanese and Han Chinese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-903 | Tablet; oral |
| DRUG | Placebo for ABBV-903 | Tablet; oral |
Timeline
- Start date
- 2023-08-23
- Primary completion
- 2023-10-30
- Completion
- 2023-10-30
- First posted
- 2023-08-24
- Last updated
- 2023-11-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06009237. Inclusion in this directory is not an endorsement.